Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 5;195(22):E773-E781.
doi: 10.1503/cmaj.221731.

Nonsurgical management of major hemorrhage

Jeannie Callum  1 , Christopher C D Evans  2 , Alan Barkun  2 , Keyvan Karkouti  2
Affiliations
Review

Nonsurgical management of major hemorrhage

Jeannie Callum et al. CMAJ. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Jeannie Callum has received research funding from Canadian Blood Services (produces and distributes blood components) and Octapharma (manufactures prothrombin complex concentrate and fibrinogen concentrates). She sits on the nominating committee with the Association for the Advancement of Blood & Biotherapies, and on the data safety monitoring boards for the TRACE (Tranexamic Acid for Subdural Hematoma) trial, a University of Ottawa pilot study of tranexamic acid for hypoproliferative thrombocytopenia, and the FEISTY (fibrinogen replacement in trauma) trial. Alan Barkun has received reimbursement for consulting from AstraZeneca and Medtronic. Keyvan Karkouti has received research funding, consulting fees and honoraria from Octapharma, and consulting fees from Werfen (provides viscoelastic point of care testing). He sits on review boards with the Canadian Institutes of Health Research and the Heart and Stroke Foundation. No other competing interests were declared.

Figures

Figure 1:
Figure 1:
Algorithm to guide activation of the massive hemorrhage protocol in patients with major hemorrhage. A Critical Administration Threshold (CAT) score of 3 or higher (CAT 3+) is defined as the need for transfusion of 3 or more red blood cells in the first hour of resuscitation. A Resuscitation Intensity (RI) score of 4 or higher is defined as the need for 4 or more of any of the following in the first 30 minutes: unit of blood (red cell, plasma or platelet), 500 mL of colloid or 1000 mL of crystalloid. The shock index is calculated as the heart rate divided by systolic blood pressure.
Figure 2:
Figure 2:
Use of tranexamic acid for major hemorrhage. Note: IV = intravenous.
Figure 3:
Figure 3:
Frequency of laboratory testing and hemostatic targets. *No suggested target in patients with cirrhosis. †More than 100 × 109/L for patients with head injury. ‡More than 2.0 g/L for postpartum hemorrhage. Note: INR = international normalized ratio.
Figure 4:
Figure 4:
Algorithm for a generic massive hemorrhage protocol for patients with major bleeding. A Critical Administration Threshold (CAT) score of 3 or higher (CAT 3+) is defined as the need for transfusion of 3 or more red blood cells in the first hour of resuscitation. A Resuscitation Intensity (RI) score of 4 or higher is defined as the need for 4 or more of any of the following in the first 30 min: unit of blood (red cell, plasma or platelet), 500 mL of colloid or 1000 mL of crystalloid. The shock index is calculated as the heart rate divided by systolic blood pressure. *If plasma is unavailable in rural settings, consider 2000 IU prothrombin complex concentrate (PCC) and 4 g of fibrinogen; avoid the use of plasma in patients with cirrhosis. †Reversal is not recommended for patients with gastrointestinal (GI) bleeding unless hemorrhage is life-threatening. ‡No suggested target for patients with cirrhosis. §>2.0 g/L for postpartum hemorrhage. Note: INR = international normalized ratio, IV = intravenous, RBC = red blood cells.
See this image and copyright information in PMC

References

    1. National Blood Authority. Patient blood management guidelines module 1: critical bleeding/massive transfusion. 2010; Canberra: National Blood Authority.
    1. D’Souza K, Norman M, Greene A, et al. . Prediction of massive transfusion with the Revised Assessment of Bleeding and Transfusion (RABT) score at Canadian level I trauma centers. Injury 2023;54:19–24. - PubMed
    1. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J thromb haemost 2005;3:692–4. - PubMed
    1. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, et al. . Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32. - PubMed
    1. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;389:2105–16. - PMC - PubMed